Lon­don biotech com­pletes $2.5M mi­cro IPO; AGTC touts ear­ly gene ther­a­py da­ta — but in­vestors keep their dis­tance

These days, you make do with what you can get from the pub­lic biotech mar­kets.

For its first flight across the pond, Lon­don-based OKYO Phar­ma raised $2.5 mil­lion from its Nas­daq IPO, pric­ing 625,000 shares at $4 a pop.

A pre­clin­i­cal play­er, the biotech is work­ing on new treat­ments for in­flam­ma­to­ry dry eye dis­eases and oc­u­lar pain.

AGTC touts ear­ly gene ther­a­py da­ta — but in­vestors are keep­ing their dis­tance

Af­ter years of dis­ap­point­ing set­backs, Ap­plied Ge­net­ic Tech­nolo­gies Corp says it fi­nal­ly has some good news to re­port — even if in­vestors are still in wait-and-see mode.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER